Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

Study summary

The purpose of this study is to look at several genes that might determine how the body processes the drugs used to treat lung, colorectal and head and neck cancers. The goal of this examination is to help investigators determine the proper dosage to give future cancer patients or to better predict which future patients will respond to particular drug therapies.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Cancer · Colorectal Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 28, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Kansas Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Kansas Medical Center
Interventions being studied: Not specified

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to receive chemotherapy as part of their treatment

Reasons someone may not be able to joinExclusion criteria

Colorectal cancer patients that have never received or will not receive chemotherapy as part of their therapy
Head and Neck cancer patients that have never received or will not receive chemotherapy as part of their treatment
Patients with cancer types other than colorectal or head and neck
Unable to give informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Kansas Medical CenterKansas City, Kansas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 28, 2016. Always confirm current availability with the study team.

View original record ↗